Skip to main content
Top
Published in: Esophagus 2/2023

07-11-2022 | Eosinophilic Esophagitis | Original Article

Esophageal mast cells may be associated with the perception of symptoms in patients with eosinophilic esophagitis

Authors: Atsushi Kanamori, Fumio Tanaka, Shingo Takashima, Akinari Sawada, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Shuhei Hosomi, Noriko Kamata, Yasuaki Nagami, Koichi Taira, Toshio Watanabe, Yasuhiro Fujiwara

Published in: Esophagus | Issue 2/2023

Login to get access

Abstract

Background

Eosinophilic esophagitis (EoE) is a type 2 helper T-cell (Th2)-mediated allergic disease that involves mast cells. This study aimed to clarify the relationship between perception of symptoms and mast cell levels in patients with EoE.

Methods

We enrolled patients with asymptomatic esophageal eosinophilia (aEE) and those with symptomatic EoE. Immunofluorescence staining was performed on esophageal biopsy specimens to quantify mast cell-related molecules, such as tryptase, proteinase-activated receptor (PAR)-2, and vasoactive intestinal peptide receptor (VPAC)-1.

Results

We evaluated 28 and 58 patients with aEE and EoE, respectively. There were no significant differences in clinical and endoscopic features and peak eosinophil counts between both groups. Mast cell tryptase-positive areas were significantly higher in EoE than in aEE (4.9 [3.5–6.2] vs. 2.0 [1.2–3.4] %, p < 0.01). The number of PAR-2-positive cells was significantly higher in EoE than in aEE (14 [8.8–20.0] vs. 4 [2.8–8.0] cells/high-power field [HPF], p < 0.01). The number of VPAC-1-positive cells was significantly higher in the EoE group than in the aEE group (13 [8.8–16.0] vs. 6 [3.0–9.3] cells/HPF, p < 0.01). A positive correlation was observed between the numbers of PAR-2-positive cells and VPAC-1-positive cells (r = 0.851, p < 0.01). Moreover, mast cell tryptase-positive areas positively correlated with the number of PAR-2- and VPAC-1-positive cells (r = 0.352, p < 0.01; r = 0.355, p < 0.01, respectively).

Conclusions

Esophageal mast cells and their receptors, PAR-2 and VPAC-1, may contribute to the perception of symptoms in patients with EoE.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022-1033.e10.CrossRefPubMed Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022-1033.e10.CrossRefPubMed
2.
go back to reference Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335–58.CrossRefPubMedPubMedCentral Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335–58.CrossRefPubMedPubMedCentral
3.
go back to reference Ishimura N, Kinoshita Y. Eosinophilic esophagitis in Japan: focus on response to acid suppressive therapy. J Gastroenterol Hepatol. 2018;33(5):1016–22.CrossRefPubMed Ishimura N, Kinoshita Y. Eosinophilic esophagitis in Japan: focus on response to acid suppressive therapy. J Gastroenterol Hepatol. 2018;33(5):1016–22.CrossRefPubMed
4.
go back to reference Kitamura H, Tanaka F, Nadatani Y, et al. Eosinophilic esophagitis and asymptomatic esophageal eosinophilia display similar immunohistological profiles. J Clin Biochem Nutr. 2021;68(3):246–52.CrossRefPubMed Kitamura H, Tanaka F, Nadatani Y, et al. Eosinophilic esophagitis and asymptomatic esophageal eosinophilia display similar immunohistological profiles. J Clin Biochem Nutr. 2021;68(3):246–52.CrossRefPubMed
5.
go back to reference Ishibashi F, Fukushima K, Onizuka R, et al. Risk of progression to eosinophilic esophagitis in patients with asymptomatic esophageal eosinophilia: a retrospective pilot study. JGH Open. 2020;4(3):422–8.CrossRefPubMed Ishibashi F, Fukushima K, Onizuka R, et al. Risk of progression to eosinophilic esophagitis in patients with asymptomatic esophageal eosinophilia: a retrospective pilot study. JGH Open. 2020;4(3):422–8.CrossRefPubMed
7.
go back to reference Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Investig. 2006;116(2):536–47.CrossRefPubMedPubMedCentral Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Investig. 2006;116(2):536–47.CrossRefPubMedPubMedCentral
8.
go back to reference Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272(7):4043–9.CrossRefPubMed Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272(7):4043–9.CrossRefPubMed
9.
go back to reference Vergnolle N, Bunnett NW, Sharkey KA, et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med. 2001;7(7):821–6.CrossRefPubMed Vergnolle N, Bunnett NW, Sharkey KA, et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med. 2001;7(7):821–6.CrossRefPubMed
10.
go back to reference Keita AV, Carlsson AH, Cigéhn M, et al. Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle-associated epithelium and during stress in rats. Neurogastroenterol Motil. 2013;25(6):e406–17.CrossRefPubMed Keita AV, Carlsson AH, Cigéhn M, et al. Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle-associated epithelium and during stress in rats. Neurogastroenterol Motil. 2013;25(6):e406–17.CrossRefPubMed
11.
go back to reference Ottaway CA, Lewis DL, Asa SL. Vasoactive intestinal peptide-containing nerves in Peyer’s patches. Brain Behav Immun. 1987;1(2):148–58.CrossRefPubMed Ottaway CA, Lewis DL, Asa SL. Vasoactive intestinal peptide-containing nerves in Peyer’s patches. Brain Behav Immun. 1987;1(2):148–58.CrossRefPubMed
12.
go back to reference Bednarska O, Walter SA, Casado-Bedmar M, et al. Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. Gastroenterology. 2017;153(4):948-960.e3.CrossRefPubMed Bednarska O, Walter SA, Casado-Bedmar M, et al. Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. Gastroenterology. 2017;153(4):948-960.e3.CrossRefPubMed
13.
go back to reference Verma AK, Manohar M, Venkateshaiah SU, et al. Role of vasoactive intestinal peptide in promoting the pathogenesis of eosinophilic esophagitis (EoE). Cell Mol Gastroenterol Hepatol. 2018;5(1):99-100.e7.CrossRefPubMed Verma AK, Manohar M, Venkateshaiah SU, et al. Role of vasoactive intestinal peptide in promoting the pathogenesis of eosinophilic esophagitis (EoE). Cell Mol Gastroenterol Hepatol. 2018;5(1):99-100.e7.CrossRefPubMed
14.
go back to reference Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489–95.CrossRefPubMed Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489–95.CrossRefPubMed
15.
go back to reference Abe Y, Iijima K, Ohara S, et al. Localized esophageal eosinophilia: Is it an early manifestation of eosinophilic esophagitis or a subtype of gastroesophageal reflux disease? Dig Endosc. 2014;26(3):337–43.CrossRefPubMed Abe Y, Iijima K, Ohara S, et al. Localized esophageal eosinophilia: Is it an early manifestation of eosinophilic esophagitis or a subtype of gastroesophageal reflux disease? Dig Endosc. 2014;26(3):337–43.CrossRefPubMed
16.
go back to reference Miwa H, Yokoyama T, Hori K, et al. Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: a validation study in a cohort of Japanese endoscopists. Dis Esophagus. 2008;21(4):355–63.CrossRefPubMed Miwa H, Yokoyama T, Hori K, et al. Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: a validation study in a cohort of Japanese endoscopists. Dis Esophagus. 2008;21(4):355–63.CrossRefPubMed
17.
go back to reference Bolton SM, Kagalwalla AF, Arva NC, et al. Mast cell infiltration is associated with persistent symptoms and endoscopic abnormalities despite resolution of eosinophilia in pediatric eosinophilic esophagitis. Am J Gastroenterol. 2020;115(2):224–33.CrossRefPubMedPubMedCentral Bolton SM, Kagalwalla AF, Arva NC, et al. Mast cell infiltration is associated with persistent symptoms and endoscopic abnormalities despite resolution of eosinophilia in pediatric eosinophilic esophagitis. Am J Gastroenterol. 2020;115(2):224–33.CrossRefPubMedPubMedCentral
18.
go back to reference Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230-6.e1-2.CrossRefPubMed Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230-6.e1-2.CrossRefPubMed
19.
go back to reference Dellon ES, Kim HP, Sperry SL, et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79(4):577-85.e4.CrossRefPubMed Dellon ES, Kim HP, Sperry SL, et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79(4):577-85.e4.CrossRefPubMed
20.
go back to reference Cairns JA. Mast cell tryptase and its role in tissue remodelling. Clin Exp Allergy. 1998;28(12):1460–3.CrossRefPubMed Cairns JA. Mast cell tryptase and its role in tissue remodelling. Clin Exp Allergy. 1998;28(12):1460–3.CrossRefPubMed
21.
go back to reference Aceves SS, Chen D, Newbury RO, et al. Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-β1, and increase esophageal smooth muscle contraction. J Allergy Clin Immunol. 2010;126(6):1198-204.e4.CrossRefPubMed Aceves SS, Chen D, Newbury RO, et al. Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-β1, and increase esophageal smooth muscle contraction. J Allergy Clin Immunol. 2010;126(6):1198-204.e4.CrossRefPubMed
22.
go back to reference Yoshida N, Katada K, Handa O, et al. Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Mol Med. 2007;19(2):335–40.PubMed Yoshida N, Katada K, Handa O, et al. Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Mol Med. 2007;19(2):335–40.PubMed
23.
go back to reference Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6(2):151–8.CrossRefPubMed Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6(2):151–8.CrossRefPubMed
24.
go back to reference Liu X, Wang J, Zhang H, et al. Induction of mast cell accumulation by tryptase via a protease activated receptor-2 and ICAM-1 dependent mechanism. Mediators Inflamm. 2016;2016:6431574.CrossRefPubMedPubMedCentral Liu X, Wang J, Zhang H, et al. Induction of mast cell accumulation by tryptase via a protease activated receptor-2 and ICAM-1 dependent mechanism. Mediators Inflamm. 2016;2016:6431574.CrossRefPubMedPubMedCentral
25.
26.
go back to reference Amadesi S, Cottrell GS, Divino L, et al. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. J Physiol. 2006;575(Pt 2):555–71.CrossRefPubMedPubMedCentral Amadesi S, Cottrell GS, Divino L, et al. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. J Physiol. 2006;575(Pt 2):555–71.CrossRefPubMedPubMedCentral
27.
go back to reference Zhang S, Shoda T, Aceves SS, et al. Mast cell-pain connection in eosinophilic esophagitis. Allergy. 2022;77(6):1895–9.CrossRefPubMed Zhang S, Shoda T, Aceves SS, et al. Mast cell-pain connection in eosinophilic esophagitis. Allergy. 2022;77(6):1895–9.CrossRefPubMed
28.
go back to reference Kulka M, Sheen CH, Tancowny BP, et al. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology. 2008;123(3):398–410.CrossRefPubMedPubMedCentral Kulka M, Sheen CH, Tancowny BP, et al. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology. 2008;123(3):398–410.CrossRefPubMedPubMedCentral
29.
go back to reference Taft TH, Carlson DA, Simons M, et al. Esophageal hypervigilance and symptom-specific anxiety in patients with eosinophilic esophagitis. Gastroenterology. 2021;161(4):1133–44.CrossRefPubMed Taft TH, Carlson DA, Simons M, et al. Esophageal hypervigilance and symptom-specific anxiety in patients with eosinophilic esophagitis. Gastroenterology. 2021;161(4):1133–44.CrossRefPubMed
30.
go back to reference Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8.PubMed Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8.PubMed
Metadata
Title
Esophageal mast cells may be associated with the perception of symptoms in patients with eosinophilic esophagitis
Authors
Atsushi Kanamori
Fumio Tanaka
Shingo Takashima
Akinari Sawada
Masaki Ominami
Yuji Nadatani
Shusei Fukunaga
Koji Otani
Shuhei Hosomi
Noriko Kamata
Yasuaki Nagami
Koichi Taira
Toshio Watanabe
Yasuhiro Fujiwara
Publication date
07-11-2022
Publisher
Springer Nature Singapore
Published in
Esophagus / Issue 2/2023
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-022-00967-w

Other articles of this Issue 2/2023

Esophagus 2/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine